NCT05167409View on ClinicalTrials.gov

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2026

Conditions
Microsatellite Stable Metastatic Colorectal Cancer
Interventions
DRUG

Evorpacept (ALX148)

IV QW

DRUG

Cetuximab

IV QW

DRUG

Pembrolizumab

IV Q3W

Trial Locations (4)

22031

Inova Schar Cancer Institute, Fairfax

80045

University of Colorado Cancer Center, Aurora

85724

University of Arizona Cancer Center, Tucson

08903

Rutgers Cancer insititute, New Brunswick

Sponsors
All Listed Sponsors
collaborator

ALX Oncology Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Criterium, Inc.

INDUSTRY

collaborator

Academic GI Cancer Consortium (AGICC)

OTHER

lead

University of Colorado, Denver

OTHER

NCT05167409 - A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter